X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

86 percent of AARP members support the Medicare rebate rule that AARP opposes

By Holly Campbell  |    June 12, 2019
Eighty-six percent of AARP members support the administration’s proposed rule to reform the rebate system in Medicare Part D, according to a nationwide Morning Consult survey commissioned by the...   Read More

New report finds 15 new oncology therapies launched last year

By Holly Campbell  |    June 5, 2019
A record 15 new oncology therapeutics launched in 2018 for 17 tumor types, according to IQVIA’s “Global Oncology Trends 2019” report. This progress includes a continued shift toward precision...   Read More

New study finds hospitals continue to push patients to costlier outpatient settings

By Holly Campbell  |    May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...   Read More

4 Things to know about the IQVIA “Medicine Use and Spending” report

By Holly Campbell  |    May 9, 2019
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient...   Read More

Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”

By Holly Campbell  |    May 9, 2019
Reinforcing our industry’s commitment to providing patients with more transparency about medicine costs, yesterday, our member companies announced the launch of the Medicine Assistance Tool, or MAT   Read More

Six policy solutions to help patients afford their insulin

By Holly Campbell  |    April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...   Read More

PhRMA comments on OIG proposed rule to reform the rebate system

By Holly Campbell  |    April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...   Read More

Five key facts about the market for insulins

By Holly Campbell  |    April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...   Read More

OIG proposed rule could help strengthen the Part D market

By Holly Campbell  |    March 28, 2019
Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...   Read More

Rebate rule would help ensure seniors with diabetes don’t pay more for their medicine than their insurer

By Holly Campbell  |    March 25, 2019
Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates